<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03739580</url>
  </required_header>
  <id_info>
    <org_study_id>DBSP-XWHCMU</org_study_id>
    <nct_id>NCT03739580</nct_id>
  </id_info>
  <brief_title>DCB Compared Stenting in Popliteal Lesions</brief_title>
  <official_title>The Comparison of Drug-coated Balloon With Stent Deployment in Popliteal Atherosclerotic Occlusive Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xuanwu Hospital, Beijing</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized prospective study aiming to compare drug-coated balloons and stent
      deployment in Popliteal atherosclerotic occlusive lesions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2016</start_date>
  <completion_date type="Anticipated">September 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary patency of claudicant patients</measure>
    <time_frame>12 months after the index procedure</time_frame>
    <description>Claudicant patients (Rutherford C1-3), primary patency defined as PSVR（peak systolic velocity ratio) ≤2.4, absence of restenosis &gt;50% based on an imaging study (Duplex ultrasound, CT angiography or catheter angiography) at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Salvage limb rate (for CLI patients)</measure>
    <time_frame>12 months after the index procedure</time_frame>
    <description>Limb Salvage is defined as the freedom from secondary major amputation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rutherford classification</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ABI</measure>
    <time_frame>12 months</time_frame>
    <description>Ankle Brachial index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TcpO2</measure>
    <time_frame>12 months</time_frame>
    <description>transcutaneous oxygen pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wagnar classification</measure>
    <time_frame>12 months</time_frame>
    <description>incision healing information of Rutherford C5-6 patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization rate</measure>
    <time_frame>12 months</time_frame>
    <description>frequency of repeat intervention or surgical treatment due to loss of patency at the target vessel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Index Limb Ischemia at 12-month Follow up</measure>
    <time_frame>12 months</time_frame>
    <description>Index Limb Ischemia is defined by Rutherford/Becker Classification categories 3 through 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Events at 12-month Post Procedure</measure>
    <time_frame>12 months</time_frame>
    <description>Major adverse events included death, index limb ischemia, index limb amputation, clinically driven target lesion revascularization, and significant embolic events, which were defined as causing end-organ damage.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Popliteal Stenosis</condition>
  <condition>Popliteal Artery Occlusion</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>drug-coating balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>drug-coating balloon (Orchid) intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>stent deployment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>metal bare stent intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DCB angioplasty (Orchid, Acotec Scientific Co. Ltd.)</intervention_name>
    <description>for popliteal stenosis/occlusive lesions, randomised received DCB or Stent deployment.</description>
    <arm_group_label>drug-coating balloon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stent (Maris,Medtronic.USA or Sinus/Supera, Germany)</intervention_name>
    <description>for popliteal stenosis/occlusive lesions, randomised received DCB or Stent deployment.</description>
    <arm_group_label>stent deployment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Symptomatic peripheral artery disease:

          -  Moderate or severe claudication (Rutherford category 2 or 3)

          -  Critical limb ischemia (Rutherford category 4 or 5)

          -  Atherosclerotic popliteal artery disease (stenosis &gt; 50%)

          -  Patients with signed informed consent

        Exclusion Criteria:

          -  Acute critical limb ischemia

          -  Severe critical limb ischemia (Rutherford category 6)

          -  Involvement of SFA disease with stenosis

          -  Continous total occlusion of all proximal infrapopliteal arteries (origin of the
             anterior tibial artery or tibioperoneal trunk).

          -  Known hypersensitivity or contraindication to any of the following medications:
             heparin, aspirin, clopidogrel, or contrast agent

          -  Age &gt; 80 years

          -  Severe hepatic dysfunction (&gt; 3 times normal reference values)

          -  Significant leucopenia, neutropenia, thrombocytopenia, anemia, or known bleeding
             diathesis

          -  LVEF &lt; 40% or clinically overt congestive heart failure

          -  Pregnant women or women with potential childbearing

          -  Life expectancy &lt;1 year due to comorbidity

          -  Previous bypass surgery or stenting for the target popliteal artery

          -  Untreated inflow disease of the ipsilateral pelvic or femoropopliteal arteries (more
             than 50% stenosis or occlusion)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongquan Gu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xuanwu hospital CMU</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianming Guo, M.D.</last_name>
    <phone>+86 1314-636-9562</phone>
    <email>guojianming@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gu Yong Quan</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian ming Guo, M.D.</last_name>
      <phone>13146369562</phone>
      <email>guojianming@aliyun.com</email>
    </contact>
    <contact_backup>
      <last_name>Yong quan Gu, M.D.</last_name>
      <phone>15901598209</phone>
      <email>gu15901598209@aliyun.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 6, 2018</study_first_submitted>
  <study_first_submitted_qc>November 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2018</study_first_posted>
  <last_update_submitted>November 13, 2018</last_update_submitted>
  <last_update_submitted_qc>November 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xuanwu Hospital, Beijing</investigator_affiliation>
    <investigator_full_name>Yong-Quan Gu</investigator_full_name>
    <investigator_title>Director, vascular suregry department</investigator_title>
  </responsible_party>
  <keyword>drug-coating balloon</keyword>
  <keyword>stent</keyword>
  <keyword>popliteal artery</keyword>
  <keyword>atherosclerotic occlusion</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

